MPL and autoimmune thrombocytopenic purpura: Romiplostim increases platelet counts through activation of the thrombopoietin receptor, leading to an increase in platelet production.5 Romiplostim (Nplate; Amgen, Thousand Oaks, CA, USA) is approved for use in the EU, USA, and other countries for the treatment of adults with ITP (chronic ITP in some non‐US countries, including the EU) who are refractory to first‐line treatments.6, 7, 8 Romiplostim is also indicated for pediatric patients aged ≥1 year with chronic ITP (EU), or those with ITP for ≥6 months (USA) who are refractory to other treatments.